Frontlight ResearchEarly access
Metastatic breast cancer trials in China
224 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peoplePlatform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 160
- Run by
- Fudan University
See details and how to joinNCT06649331 - Phase 1Taking peopleA Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- Where
- Guangzhou, Shanghai
- Age
- 18 years to 75 years
- People
- 36
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT05470348 - Phase 1/2Taking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Nanjing, Xian
- Age
- 18 years to 100 years
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - No phaseNot yet taking people in ChinaA Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
- Where
- Beijing, Chengdu, Dalian, Hefei, Luzhou, Nanjing, Shanghai, Tianjin, Wenzhou, Xi’an, Xuzhou, Zigong
- Age
- 18 years and over
- People
- 30
- Run by
- Shuangyue Liu
See details and how to joinNCT07782086 - No phaseTaking peopleCapecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 86
- Run by
- Wenjin Yin
See details and how to joinNCT05876065 - Phase 3Taking peopleMegestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 132
- Run by
- Sun Yat-sen University
See details and how to joinNCT07543536 - Phase 2Not yet taking people in ChinaTrastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Fujian Cancer Hospital
See details and how to joinNCT07766772 - Phase 2Taking peopleMetronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 73
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07602907 - No phaseTaking peopleA Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.
- Where
- Nanjing
- Age
- 18 years and over
- People
- 2,000
- Run by
- AstraZeneca
See details and how to joinNCT07743944 - Phase 2Not yet taking people in ChinaCulmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
- Where
- Anyang, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Nanjing, Shijiazhuang, Zhengzhou
- Age
- 18 years to 80 years
- People
- 40
- Run by
- Sun Yat-sen University
See details and how to joinNCT07745257 - Phase 2Taking peopleCulmerciclib in HR+/HER2+ Advanced Breast Cancer
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 35
- Run by
- Sun Yat-sen University
See details and how to joinNCT07732491 - Phase 1/2Taking peopleGQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 32
- Run by
- Fudan University
See details and how to joinNCT05575804 - Phase 2Taking peopleA Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 200
- Run by
- Akeso
See details and how to joinNCT07591090 - Phase 1/2Taking peopleEntinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 94
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07708194 - Phase 2Taking peopleSKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
- Where
- Shanghai
- Age
- 18 years and over
- People
- 48
- Run by
- Fudan University
See details and how to joinNCT07182721 - Phase 2Taking peopleStudy of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 113
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06433609 - Phase 2Taking peopleA Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 95
- Run by
- Fudan University
See details and how to joinNCT06889610 - Phase 2Taking peopleAn Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
- Where
- Shanghai
- Age
- 18 years and over
- People
- 60
- Run by
- Fudan University
See details and how to joinNCT07117630 - Phase 4Taking peopleReal-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 500
- Run by
- Peking University People's Hospital
See details and how to joinNCT07600164 - No phaseNot yet taking people in ChinaResearch on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
- Where
- Hangzhou
- People
- 900
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07689929 - Phase 3Not yet taking people in ChinaEfficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 308
- Run by
- Beijing Biostar Pharmaceuticals Co., Ltd.
See details and how to joinNCT07684456 - Phase 3Taking peopleA Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Where
- Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Deyang, Fuyang, Fuzhou, Ganzhou, Guangzhou, Guiyang, Handan, Hangzhou, Harbin, Hefei, Jinan, Jinzhou, Kunming, Linqing, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Neijiang, Ningbo, Qingdao, Qingzhou, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Suining, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xi’an, Xingtai, Xinxiang, Xuchang, Xuzhou, Yantai, Yongzhou, Zhengzhou
- Age
- 18 years to 75 years
- People
- 228
- Run by
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
See details and how to joinNCT07673029 - Phase 2Taking peopleOptimal Application Timing of ADC Drugs for Advanced Breast Cancer
- Where
- Shenyang
- Age
- 18 years to 75 years
- People
- 120
- Run by
- Liaoning Cancer Hospital & Institute
See details and how to joinNCT07657130 - No phaseTaking peopleA Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 60
- Run by
- Fudan University
See details and how to joinNCT07653893 - Phase 2Taking peopleA Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
- Where
- Harbin
- Age
- 18 years and over
- People
- 36
- Run by
- CSPC Megalith Biopharmaceutical Co.,Ltd.
See details and how to joinNCT07597629